Table 2.
Outcome data on mortality
| Number of patients in final analysis | GA at delivery (wk + d) (mean ± SD or median [IQR]) | Birthweight (g) (mean ± SD or median [IQR]) | Antenatal death | Live born | Neonatal death | Survival at discharge | |
|---|---|---|---|---|---|---|---|
| Ali et al9 |
73 7/80 lost to follow up |
Group 1 (n = 34) mean 36 ± 0.9 Group 2 (n = 34) mean 36 ± 0.7 |
Group 1 (n = 34) mean 2022 ± 25 Group 2 (n = 34) mean 2324 ± 19 |
0/73 = 0% | 73/73 = 100% | 5/73 = 6.8% | 68/73 = 93.2% |
| Ali et al8 |
55 5/60 lost to follow up |
Group 1 (n = 25) mean 36.8 ± 0.8 Group 2 (n = 20) mean 34.8 ± 0.6. (among surviving babies) |
Group 1 (n = 25) mean 1854 ± 262 Group 2 (n = 20) mean 1694 ± 169 (among surviving babies) |
0/55 = 0% | 55/55 = 100% | 10/55 = 18.2% | 45/55 = 81.8% |
| Aoki et al14 | 17 | Median 27.3 (23.7‐29.3) wk | Median 568 g (300‐764) | 1/17 = 5.9% | 16/17 = 94.1% | 2/16 = 12.5% | 14/17 = 82.4% |
| Baschat et al22 | 44 |
Median 29+6 (range 26+4 to 37+6) for live birth Median 26+6 (range 25+1 to 28) for stillbirth |
Median 725 (range 420‐2260) | 10/44 = 22.7% | 34/44 = 77.3% | 1/34 = 2.9% | 33/44 = 75.0% |
| Belghiti et al23 | 10 with reported outcome | Median 26+2 (25+6 to 26+6) | Median 507 (429‐553) | 1/10 = 10.0% | 9/10 = 90.0% | 6/9 = 66.7%, of which 4 intrapartum death | 3/10 = 30.0% |
| Fox et al17 | 252 | Mean 39.2 ± 2.4 | Mean 2999 ± 682 g | 4/252 (1.6%) | 248/252 (98.4%) | 2/248 = 0.8% | 246/252 = 97.6% |
| Fujisaki et al24 | 14 | Median 29+0 (26+6 to 35+3) | Median 604 (437‐1340) | 2/14 = 14.3% | 12/14 = 85.7% | 1/12 = 8.3% | 11/14 = 78.6% |
| Groom et al11 | 122 |
Group 1 (n = 63): Mean 31+5 ± 4+4 Group 2 (n = 59): Mean 31+2 ± 4+4 |
Group 1 (n = 63): 1233 ± 774 Group 2 (n = 59): 1184 ± 823 |
19/122 = 15.6% | 103/122 = 84.4% | 9/103 = 8.7% | 94/122 = 77.0% |
| Hasegawa et al25 | 26 |
Group 1 (n = 17) median 28.7 (24.7‐31.7) Group 2 (n = 9) median 28.5 (26.1‐32.4) |
Group 1 (n = 18) median 695 (424‐1016) g Group 2 (n = 8) median 568 (426‐654) g |
1/26 = 3.8% | 25/26 = 96.2% | 1/25 = 4% | 24/26 = 92.3% |
| Herraiz et al26 |
73 1/74 lost to follow up |
Group 1 (FGR) mean 30.1 ± 3.2 Group 2 (FGR+PE) mean 29.4 ± 2.5 |
Group 1 (FGR): mean 994 ± 419 Group 2 (FGR+PE): 925 ± 308 |
4/73 = 5.5% (1 TOP and 3 IUFD) | 69/73 = 94.5% | 6/69 = 8.7% | 63/73 = 86.3% |
| Kubo et al27 | 8 | Median 37+0 (35+2 to 37+0) | Median 2157 (1553‐2281) | 0/8 = 0% | 8/8 = 100% | 0/8 = 0% | 8/8 = 100% |
| Lawin‐O'Brien et al28 |
245 79/324 lost to follow up |
128 (52.2%) <28+0 53 (21.6%) 28+1 to 32+0 24 (9.8%) 32+1 to 36+0 36 (14.7%) >36+0 |
Survived: Median 1020 g (range 435‐3420) Neonatal death: median 560 (range 313‐2550) Fetal death median 422 (range 155‐2570) Feticide/TOP median 345 (range 220‐512) |
89 fetal death and 33 feticide/TOP = 122/245 = 49.8% | 123/245 = 50.2% | 22/123 = 17.9% | 101/245 = 41.2% |
| Lees et al10 |
503 9/511 lost to follow up |
Mean 30+5 ± 16 | Mean 1013 ± 321 g | 12/503 = 2.4% | 491/503 = 97.6% | 27/490 = 5.5% (1 live‐born lost to follow up) | 463/503 = 92.0% |
| Maged et al29 | 50 |
Group 1 (n = 25): Mean 35.3 ± 1.8 Group 2 (n = 25): Mean 34.8 ± 1.9 |
Group 1 (n = 25): Mean 2067 ± 352 Group 2 (n = 25): 1733 ± 361 |
4/50 = 8.0% | 46/50 = 92.0% | 4/46 = 8.7% | 42/50 = 84.0% |
| Petersen et al30 | 33 patients, with 36 pregnancies |
IUFD: Median 25 wk (range 21‐27) Live birth: Median 27 wk (range 24‐31) |
IUFD: Median 308 (range 170‐480) Live birth: Median 486 (320‐553) |
19/36 = 52.8% | 17/36 = 47.2% | 12/17 = 70.6% | 5/36 = 13.9% |
| Rizzo et al31 | 31 | Median 28.3 wk (range 23.6‐30.4) | Median 590 g (range 312‐915) | 7/31 = 22.6% | 24/31 = 77.4% | 3/24 = 12.5% | 21/31 = 67.7% |
| Savchev et al32 | 211 | Mean 34.6 ± 8.0 wk | Mean 1647 ± 765 g | 9/211 = 4.3% | 202/211 = 95.7% | 6/202 = 3.0% | 196/92.9% |
| Sharp et al12 | 135 |
Group 1 (n = 70): Median 28.1 (26.7‐29.7) Group 2 (n = 65): Median 28.4 (27.3‐30.1) |
Group 1 (n = 70): Median 604 (496‐766) Group 2 (n = 65): Median 590 (430‐842) |
43/135 = 31.9% | 92/135 = 68.1% | 17/92 = 18.5% | 75/135 = 55.6% |
| Simonazzi et al13 | 16 |
Group 1 (n = 4) median 34 wk (30‐36) Group 2 (n = 11) median 28 wk (24‐30) |
Group 1 (n = 4) median 1598 g (1100‐1750) Group 2 (n = 11) median 630 g (408‐951) |
1/16 TOP = 6.25% | 15/16 = 93.8% | 3/15 = 20% | 12/16 = 75.0% |
| Story et al33 | 20 |
Survived (n = 12): median 32+0 (range 27+1 to 39+0) Neonatal death (n = 2): 26 wk and 31+5 IUFD (n = 6): median 26 (range 24+2 to 27+2) |
Survived (n = 12): median 980 (range 720‐2090) Neonatal death (n = 2): 620 and 1050 Fetal death (n = 6): median 450 (range 424‐530) |
6/20 = 30% | 14/20 = 70% | 2/14 = 14.3% | 12/20 = 60.0% |
| Takahashi et al34 | 18 | Median 28.5 wk (26.0‐30.3) | Median 625 g (3630‐850) | 5/18 = 27.8% | 13/18 = 72.2% | 2/13 = 15.4% | 11/18 = 61.1% |
| Temming et al35 | 355 | Mean 37.2 ± 3.4 | Mean 2725 ± 763 g | 9/355 (2.5%) | 346/355 (97.5%) | 5/346 (1.4%) | 341/355 = 96.1% |
| Von Dadelszen et al36 | 27 |
Group 1 (n = 17): median 25+6 (23+5 to 29+5) Group 2 (n = 10): median 27+1 (25+4 to 32+6) |
Not described | 14/27 = 51.9% | 13/27 = 48.1% | 2/13 = 15.4% | 11/27 = 40.7% |
| Yildirim et al37 | 300 |
Group 1 (n = 137): median 32.8 (95% CI 32.3‐33.3) wks Group 2 (n = 163): median 31.3 (95% CI 30.84‐31.7) wk |
Group 1 (n = 137) median 1390 (95% CI 1308‐1473) g Group 2 (n = 163) median 1071 (95% CI 1011‐1131) g |
58/300 = 19.3% (perinatal death) | 242/300 = 80.7% |
29/242 = 12.0% 9 deaths >28 d (9/242 = 3.7%) |
204/300 = 68.0% |
| Zhang‐Rutledge et al38 | 254 |
Group 1 (n = 91): 37.1 Group 2 (n = 163): 38.3 (not described whether means or medians are presented) |
Group 1 (n = 91): Average 2605 Group 2 (n = 163): Average 2936 |
4/254 = 1.6% | 250/254 = 98.4% | 6/250 = 2.4% | 244/254 = 96.1% |
Abbreviations: FGR, fetal growth restriction; GA, gestational age; IQR, interquartile range; IUFD, intrauterine fetal death; PE, preeclampsia; SD, standard deviation; TOP, termination of pregnancy.